Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Type:
Grant
Filed:
June 20, 2002
Date of Patent:
February 24, 2009
Assignee:
Genentech, Inc.
Inventors:
Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, William I. Wood
Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Type:
Grant
Filed:
May 7, 2002
Date of Patent:
February 24, 2009
Assignee:
Genentech, Inc.
Inventors:
Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, William I. Wood
Abstract: The present invention involves the identification and preparation of vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel polypeptide related to vascular endothelial growth factor (VEGF) and bone morphogenetic protein 1. VEGF-E has homology to VEGF including conservation of the amino acids required for activity of VEGF. VEGF-E can be useful in wound repair, as well as in the generation and regeneration of tissue.
Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Type:
Grant
Filed:
December 20, 2005
Date of Patent:
February 17, 2009
Assignee:
Genentech, Inc.
Inventors:
Audrey Goddard, Paul Godowski, Christopher Grimaldi, Austin Gurney, William I. Wood
Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Type:
Grant
Filed:
September 12, 2002
Date of Patent:
February 17, 2009
Assignee:
Genentech, Inc.
Inventors:
Kevin P. Baker, Dan L. Eaton, Ellen Filvaroff, Audrey Goddard, J. Christopher Grimaldi, Austin L. Gurney, Victoria Smith, Jean Philippe Stephan, Colin K. Watanabe, William I. Wood, Zemin Zhang, Sherman Fong
Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Type:
Grant
Filed:
November 19, 2001
Date of Patent:
February 17, 2009
Assignee:
Genentech, Inc.
Inventors:
Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Timothy A. Stewart, Colin K. Watanabe, William I. Wood
Abstract: Pyrazolyl compounds of Formulas Ia and Ib are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using pyrazolyl compounds for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
Type:
Grant
Filed:
February 2, 2006
Date of Patent:
February 17, 2009
Assignees:
Array Biopharma Inc., Genentech, Inc.
Inventors:
Ellen Laird, Joseph P. Lyssikatos, Mike Welch, Jonas Grina, Josh Hansen, Brad Newhouse, Alan Olivero, George Topalov
Abstract: This invention relates to a novel human deoxyribonuclease, referred to as human DNase II. The invention provides nucleic acid sequences encoding human DNase II, thereby enabling the production of human DNase II by recombinant DNA methods in quantities sufficient for clinical use. The invention also relates to pharmaceutical compositions and diagnostic and therapeutic uses of human DNase II.
Abstract: Methods of using synergistically effective amounts of Apo-2L receptor agonists and CPT-11 to induce apoptosis and suppress growth of cancer cells, are provided.
Type:
Application
Filed:
October 14, 2008
Publication date:
February 12, 2009
Applicant:
Genentech, Inc.
Inventors:
Avi J. Ashkenazi, Mark Benyunes, Ralph Schwall
Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
Type:
Application
Filed:
June 14, 2006
Publication date:
February 12, 2009
Applicant:
Genentech, Inc.
Inventors:
Mark S. Dennis, William Mallet, Paul Polakis
Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Type:
Grant
Filed:
May 8, 2002
Date of Patent:
February 10, 2009
Assignee:
Genentech, Inc.
Inventors:
Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, Colin K. Watanabe, William I. Wood
Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Type:
Grant
Filed:
October 16, 2001
Date of Patent:
February 10, 2009
Assignee:
Genentech, Inc.
Inventors:
Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Ivar J. Kljavin, William I. Wood
Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Type:
Grant
Filed:
December 7, 2001
Date of Patent:
February 10, 2009
Assignee:
Genentech, Inc.
Inventors:
Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Colin K. Watanabe, William I. Wood
Abstract: The present application describes methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies, and chemotherapeutic agents.
Type:
Grant
Filed:
May 5, 2006
Date of Patent:
February 3, 2009
Assignee:
Genentech, Inc.
Inventors:
Camellia W. Adams, Leonard G. Presta, Mark Sliwkowski
Abstract: A method for reducing leaching of protein A during protein A affinity chromatography is described which involves reducing temperature or pH of, or by adding one or more protease inhibitors to, a composition that is subjected to protein A affinity chromatography.
Type:
Grant
Filed:
June 24, 2004
Date of Patent:
February 3, 2009
Assignee:
Genentech, Inc.
Inventors:
Robert L. Fahrner, Amy Laverdiere, Paul J. McDonald, Rhona M. O'Leary
Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
Type:
Application
Filed:
July 15, 2008
Publication date:
January 29, 2009
Applicant:
Genentech, Inc.
Inventors:
Yvonne Chen, Mark Dennis, David Dornan, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson, Bing Zheng
Abstract: The present invention provides monoclonal antibodies, and portions thereof, which are capable of specifically binding to human vascular endothelial cell growth factor (hVEGF) or hVEGF-related protein. The invention also provides hybridoma cell lines that produce such monoclonal antibodies. The monoclonal antibodies of the invention are useful as therapeutic agents, either by themselves or in conjunction with cytotoxic or other chemotherapeutic agents, to treat diseases that are characterized by excessive vascular endothelial cell proliferation. The monoclonal antibodies of the invention also are useful in diagnostic and analytical methods for determining the presence of hVEGF or hVEGF related-protein in a test sample.
Abstract: The invention provides variant CDRs comprising highly restricted amino acid sequence diversity. These polypeptides provide a flexible and simple source of sequence diversity that can be used as a source for identifying novel antigen binding polypeptides. The invention also provides these polypeptides as fusion polypeptides to heterologous polypeptides such as at least a portion of phage or viral coat proteins, tags and linkers. Libraries comprising a plurality of these polypeptides are also provided. In addition, methods of and compositions for generating and using these polypeptides and libraries are provided.